Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

Windtree Therapeutics, Inc. (NasdaqCM: WINT) showcased encouraging results from the Phase 2b SEISMiC study of istaroxime, its novel investigational therapy for early cardiogenic shock, at the ...

Explore the latest innovations in cardiogenic shock treatment, including advances in mechanical circulatory support devices, ...